The acting chief executive of South Africa’s OBP is placed on precautionary suspension following allegations related to the pricing of foot-and-mouth disease (FMD) vaccines. The board gives him five days to respond to the allegations.
Reporting states that the dispute centres on claims that OBP imported the vaccines at a lower cost but sold them to farmers at higher prices. The outlets describe the move as precautionary, indicating an internal process while the matter is assessed and the CEO is given an opportunity to respond.
While the articles focus on the suspension and the board’s timeframe, they differ mainly in emphasis. One outlet frames the issue as a “pricing row,” highlighting the alleged cost-to-selling price gap, while another explains what led to the suspension by outlining the allegations under consideration. No source presented additional evidence or outcomes beyond the suspension and the CEO’s response period.
